Pfizer Drugs - Search News

Pfizer, Albert Bourla

Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's obesity and oncology drugs.

Reuters on MSN · 4d

Pfizer going 'all in' on obesity drug development, CEO Bourla says

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday.

Business Insider · 3d

Pfizer CEO Bourla says Starboard Value wants minimal changes, Bloomberg says

CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the

CNBC on MSN · 4d

Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.

Ozempic Among Next Drugs Up for Medicare Price Negotiations

The Hill on MSN · 11h

The next 15 drugs chosen for Medicare negotiation

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before the inauguration of President-elect Trump. The Centers for Medicare

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.

Orange County Register · 10h

Ozempic and Wegovy among drugs on Medicare list getting price cuts

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

2don MSN

Why Pfizer sold its $3 billion stake in Haleon

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

BioPharma Dive7d

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Indiana attorney general sues drug companies over EpiPen prices

The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results